| Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. CAL Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V ... N Engl J Med. 382, 1894-1905, 2020 | 4691* | 2020 |
| Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial AB El-Khoueiry, B Sangro, T Yau, TS Crocenzi, M Kudo, C Hsu, TY Kim, ... The Lancet 389 (10088), 2492-2502, 2017 | 3948 | 2017 |
| Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial RS Finn, BY Ryoo, P Merle, M Kudo, M Bouattour, HY Lim, V Breder, ... Journal of Clinical Oncology 38 (3), 193-202, 2020 | 1439 | 2020 |
| Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial T Yau, YK Kang, TY Kim, AB El-Khoueiry, A Santoro, B Sangro, I Melero, ... JAMA oncology 6 (11), e204564-e204564, 2020 | 915 | 2020 |
| Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised … J Li, S Qin, R Xu, TCC Yau, B Ma, H Pan, J Xu, Y Bai, Y Chi, L Wang, ... The lancet oncology 16 (6), 619-629, 2015 | 785 | 2015 |
| Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma T Yau, VYF Tang, TJ Yao, ST Fan, CM Lo, RTP Poon Gastroenterology 146 (7), 1691-1700. e3, 2014 | 741 | 2014 |
| CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular … T Yau, JW Park, RS Finn, AL Cheng, P Mathurin, J Edeline, M Kudo, ... Annals of Oncology 30, v874-v875, 2019 | 737 | 2019 |
| Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial T Yau, JW Park, RS Finn, AL Cheng, P Mathurin, J Edeline, M Kudo, ... The Lancet Oncology 23 (1), 77-90, 2022 | 657 | 2022 |
| A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer R Pang, WL Law, ACY Chu, JT Poon, CSC Lam, AKM Chow, L Ng, ... Cell stem cell 6 (6), 603-615, 2010 | 639 | 2010 |
| Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 … ES Group. Lancet Oncology 17 (3), 367-377, 2016 | 631 | 2016 |
| Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma GK Abou-Alfa, G Lau, M Kudo, SL Chan, RK Kelley, J Furuse, ... NEJM evidence 1 (8), EVIDoa2100070, 2022 | 514 | 2022 |
| Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with≥ 2 HER2-directed regimens: phase III NALA trial C Saura, M Oliveira, YH Feng, MS Dai, SW Chen, SA Hurvitz, SB Kim, ... Journal of Clinical Oncology 38 (27), 3138, 2020 | 451 | 2020 |
| Pembrolizumab (keytruda) G Kwok, TCC Yau, JW Chiu, E Tse, YL Kwong Human vaccines & immunotherapeutics 12 (11), 2777-2789, 2016 | 340 | 2016 |
| Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I/II study RK Kelley, B Sangro, W Harris, M Ikeda, T Okusaka, YK Kang, S Qin, ... Journal of Clinical Oncology 39 (27), 2991, 2021 | 308 | 2021 |
| SARS-CoV-2 infects human neural progenitor cells and brain organoids BZ Zhang, H Chu, S Han, H Shuai, J Deng, Y Hu, H Gong, ACY Lee, ... Cell research 30 (10), 928-931, 2020 | 295 | 2020 |
| Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial RK Kelley, L Rimassa, AL Cheng, A Kaseb, S Qin, AX Zhu, SL Chan, ... The Lancet Oncology 23 (8), 995-1008, 2022 | 286 | 2022 |
| Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma B Sangro, I Melero, S Wadhawan, RS Finn, GK Abou-Alfa, AL Cheng, ... Journal of hepatology 73 (6), 1460-1469, 2020 | 285 | 2020 |
| Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. AB El-Khoueiry, I Melero, TS Crocenzi, TH Welling, TC Yau, W Yeo, ... Journal of Clinical Oncology 33 (18_suppl), LBA101-LBA101, 2015 | 273 | 2015 |
| Nivolumab (NIVO)+ ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. T Yau, YK Kang, TY Kim, AB El-Khoueiry, A Santoro, B Sangro, I Melero, ... Journal of Clinical Oncology 37 (15_suppl), 4012-4012, 2019 | 246 | 2019 |
| Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma AX Zhu, AR Abbas, MR de Galarreta, Y Guan, S Lu, H Koeppen, W Zhang, ... Nature medicine 28 (8), 1599-1611, 2022 | 214 | 2022 |
Bruno SangroProfessor of Medicine, Universidad de NavarraVerified email at unav.es
